Previous Close | 8.50 |
Open | 8.50 |
Bid | 1.10 |
Ask | 5.40 |
Strike | 30.00 |
Expire Date | 2024-07-19 |
Day's Range | 8.50 - 8.50 |
Contract Range | N/A |
Volume | |
Open Interest | 12 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Insights into Financial Performance and Strategic Developments
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda